Vistagen reports fiscal year 2025 third quarter financial results and corporate update

South san francisco, calif.--(business wire)--vistagen (nasdaq: vtgn), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended december 31, 2024, and provided a corporate update. “we had a very productive quarter, with both palisade-3 and palisade-4 advancing towards expected top-line.
VTGN Ratings Summary
VTGN Quant Ranking